CN110895283A - High-sensitivity D-dimer detection kit and use method thereof - Google Patents
High-sensitivity D-dimer detection kit and use method thereof Download PDFInfo
- Publication number
- CN110895283A CN110895283A CN201911260674.4A CN201911260674A CN110895283A CN 110895283 A CN110895283 A CN 110895283A CN 201911260674 A CN201911260674 A CN 201911260674A CN 110895283 A CN110895283 A CN 110895283A
- Authority
- CN
- China
- Prior art keywords
- hole
- washing
- solid phase
- phase carrier
- well
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 52
- 239000003154 D dimer Substances 0.000 title claims abstract description 30
- 108010052295 fibrin fragment D Proteins 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000005406 washing Methods 0.000 claims abstract description 42
- 239000007790 solid phase Substances 0.000 claims abstract description 41
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 15
- 239000005017 polysaccharide Substances 0.000 claims abstract description 15
- 230000001681 protective effect Effects 0.000 claims abstract description 13
- 238000007789 sealing Methods 0.000 claims abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 16
- 238000004140 cleaning Methods 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- 239000011534 wash buffer Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 108010090804 Streptavidin Proteins 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 239000010453 quartz Substances 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 229920004890 Triton X-100 Polymers 0.000 claims description 5
- 239000013504 Triton X-100 Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000012921 fluorescence analysis Methods 0.000 claims description 3
- 239000011888 foil Substances 0.000 claims description 3
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- -1 polysaccharide compound Chemical class 0.000 abstract description 6
- 230000003993 interaction Effects 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 2
- 239000001257 hydrogen Substances 0.000 abstract description 2
- 239000007853 buffer solution Substances 0.000 description 8
- 238000002372 labelling Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000004816 latex Substances 0.000 description 5
- 229920000126 latex Polymers 0.000 description 5
- 230000020764 fibrinolysis Effects 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000003480 fibrinolytic effect Effects 0.000 description 3
- 238000012123 point-of-care testing Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000003126 immunogold labeling Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 229940071089 sarcosinate Drugs 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004122 cyclic group Chemical class 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108010073651 fibrinmonomer Proteins 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a high-sensitivity D-dimer detection kit and a use method thereof, the kit comprises a kit main body, a sealing cover, a protective cover and reagents, wherein the kit main body is sequentially provided with a solid phase carrier hole, a sample hole, an antibody detection hole, a fluorescein hole, a washing hole and a reading hole; the surface of the solid phase carrier is coated with the polysaccharide compound with biocompatibility, and the polysaccharide compound can form hydrogen bond weak interaction with protein molecules, so that specific immune signals are effectively enhanced.
Description
Technical Field
The invention relates to the field of in-vitro diagnosis, in particular to a high-sensitivity D-dimer detection kit and a use method thereof.
Background
The D-dimer is derived from a plasmin-solubilized crosslinked fibrin clot, is a specific degradation product generated by fibrin monomer after crosslinking by activated factor XIIIa and then hydrolyzing by plasmin, and is a specific fibrinolysis process marker.
Under physiological state, the organism keeps the dynamic balance of coagulation and fibrinolysis to ensure the timely formation and elimination of fibrin, the normal D-dimer level of human body is generally below 200 mug/l, if the coagulation and fibrinolysis system is doubly activated in vivo, the D-dimer level will be increased, therefore, the D-dimer can be used as one of the molecular markers of hypercoagulability and hyperfibrinolysis in vivo, the specificity of the D-dimer reflects the common pathological characteristics of the diseases with the processes of coagulation and fibrinolysis, thus the clinical application is very wide. D-dimer is used as a main factor for determining the fibrinolytic system and has important significance for diagnosing and treating diseases of the fibrinolytic system and diseases related to the fibrinolytic system and detecting thrombolytic therapy, so that the D-dimer is a key index of Deep Venous Thrombosis (DVT), Pulmonary Embolism (PE) and Disseminated Intravascular Coagulation (DIC). Therefore, the determination of the content of the D-dimer in the blood has important clinical significance for early diagnosis and disease course monitoring of thrombotic diseases, treatment monitoring of thrombolytic drugs and the like.
At present, the detection methods for the D-dimer mainly comprise a latex agglutination method, a double antibody sandwich method (ELISA), an immune gold labeling method, a latex particle enhanced immunoturbidimetry method and the like. The latex agglutination method is simple and rapid, is suitable for point-of-care testing (POCT), but can be only used for qualitative determination, and is mostly used for screening; the ELISA method has high sensitivity, but has poor quantitative accuracy, long operation time and low automation level, and is not suitable for the requirements of POCT; the latex particle enhanced immunoturbidimetry can be conveniently applied to a full-automatic biochemical analyzer, but needs instruments, is long in time consumption, is suitable for processing a large number of samples, and cannot meet the aim of rapid detection in emergency departments and primary hospitals; the immuno-gold labeling method is similar to the latex agglutination method, and has the advantages of simple and rapid operation, but the disadvantage of poor quantitative accuracy, especially poor repeatability, limits the clinical application of the immuno-gold labeling method, and is particularly not suitable for the quantitative detection of the humoral marker protein which needs to be accurately quantified to help the diagnosis of diseases. Therefore, the development of a D dimer detection product with accurate quantification, rapidness and convenience is still an important problem to be solved urgently in the field of clinical diagnosis product research.
Disclosure of Invention
The invention aims to provide a high-sensitivity D-dimer detection kit and a using method thereof, and the detection kit has high sensitivity and good linearity.
In order to achieve the purpose, the technical scheme of the invention provides a high-sensitivity D-dimer detection kit, which comprises a kit main body, a sealing cover, a protective cover and a reagent, wherein the kit main body is sequentially provided with a solid phase carrier hole, a sample hole, a detection antibody hole, a fluorescein hole, a washing hole and a reading hole, the inside of the solid phase carrier hole is of a T-shaped structure, the protective cover is arranged above the solid phase carrier hole and is hinged with the solid phase carrier hole, a solid phase carrier is arranged in the solid phase carrier hole, a serum sample is filled in the sample hole, a biotin-labeled detection antibody is filled in the detection antibody hole, streptavidin labeled with fluorescein is filled in the fluorescein hole, the number of the washing holes is 8, a washing buffer solution is filled in the washing holes, the bottom of the reading hole is transparent, and the sealing cover completely covers the sample hole, the detection antibody hole, the, Fluorescein well, wash well, read well orifice.
Preferably, the solid phase carrier is a quartz needle.
Preferably, the protective cover is a protective aluminum foil.
Preferably, the lower end part of the solid phase carrier is coated with a polysaccharide complex, and the polysaccharide complex is a deionized water solution containing 0.5-2.5% of chitosan, 0.1-0.5% of glycerol and 0.5-1.5% of polyethylene glycol 1000 by mass.
Preferably, the washing buffer solution is PBS buffer solution (0.01M, pH7.4) containing 0.15-0.35M NaCl, 0.05-0.1% vol triton X-100 and 3-6 g/L sodium dodecyl sarcosinate.
Preferably, the diameter of each of the sample well, the detection antibody well and the fluorescein well is d1, the diameter of the washing well is d2, the diameter of the reading well is d3, the diameter of the solid phase carrier well is d4, the maximum diameter of the solid phase carrier is d5, and d5 > d3 > d1 is d4 > d 2.
A method for using a high-sensitivity D-dimer detection kit comprises the following steps: injecting a serum sample into a sample hole, putting a solid phase carrier coated with a capture antibody into the sample hole, taking out after 10-60s, sequentially oscillating and cleaning in a first washing hole, a second washing hole and a third washing hole, putting into a detection antibody hole after cleaning, taking out after 10-60s, sequentially oscillating and cleaning in a fourth washing hole and a fifth washing hole, putting into a streptavidin labeled with fluorescein after cleaning for 10-60s, taking out, sequentially oscillating and cleaning in a sixth washing hole, a seventh washing hole and an eighth washing hole, airing, putting into a reading hole, and detecting by adopting a fluorescence analysis detector.
The invention has the following beneficial effects: the surface of the quartz needle is covered with a biocompatible polysaccharide compound, the polysaccharide compound can form a hydrogen bond weak interaction with protein molecules, so that nonspecific adsorption is reduced, the polysaccharide compound can effectively enhance a specific immune signal, and the amplification of a detection signal is realized by forming a plurality of layers of fluorescein-streptavidin molecular layers on the surface of the polysaccharide compound; according to the invention, SDS and Triton-X100 with strong washing capacity are added into the washing buffer solution, the ionic strength of the washing solution is improved, the nonspecific interaction between molecules is effectively controlled, the low background and high signal-to-noise ratio of the detection result are further realized, and the sensitivity and accuracy of the detection are improved.
Drawings
FIG. 1 is a schematic structural diagram of a kit according to the present invention;
FIG. 2 is another schematic view of the structure of the kit of the present invention;
FIG. 3 is a standard curve diagram of the kit of the present invention for detecting different D-dimer standards.
In the figure: 1-solid support well, 2-protective cap, 3-solid support, 4-sample well, 5-detection antibody well, 6-fluorescein well, 7-first wash well, 8-second wash well, 9-third wash well, 10-fourth wash well, 11-fifth wash well, 12-sixth wash well, 13-seventh wash well, 14-eighth wash well, 15-reading well, 16-sealing cap.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below.
Fluorescein-labeled streptavidin was purchased from Solarbio under the cat # SF068-0.1 ml.
Example 1
A high-sensitivity D-dimer detection kit comprises a kit main body, a sealing cover, a protective cover and a reagent, wherein the kit main body is sequentially provided with a solid phase carrier hole, a sample hole, a detection antibody hole, a fluorescein hole, a washing hole and a reading hole, the interior of the solid phase carrier hole is of a T-shaped structure, a protective cover is arranged above the solid phase carrier hole and is hinged with the solid phase carrier hole, a solid phase carrier is arranged in the solid phase carrier hole, the sample hole is filled with a serum sample, the detection antibody hole is filled with a biotin-labeled detection antibody, the fluorescein holes are filled with streptavidin marked by fluorescein, the number of the washing holes is 8, the washing buffer solution is filled in the washing holes, the bottom of the reading hole is transparent, and the sealing cover completely covers the orifices of the sample hole, the detection antibody hole, the fluorescein hole, the washing hole and the reading hole.
Preferably, the solid phase carrier is a quartz needle.
Preferably, the protective cover is a protective aluminum foil.
Preferably, the lower end part of the solid phase carrier is coated with a polysaccharide complex, and the polysaccharide complex is a deionized water solution containing 0.5-2.5% of chitosan, 0.1-0.5% of glycerol and 0.5-1.5% of polyethylene glycol 1000 by mass.
Preferably, the washing buffer solution is PBS buffer solution (0.01M, pH7.4) containing 0.15-0.35M NaCl, 0.05-0.1% vol triton X-100 and 3-6 g/L sodium dodecyl sarcosinate.
Preferably, the diameter of each of the sample well, the detection antibody well and the fluorescein well is d1, the diameter of the washing well is d2, the diameter of the reading well is d3, the diameter of the solid phase carrier well is d4, the maximum diameter of the solid phase carrier is d5, and d5 > d3 > d1 is d4 > d 2.
The kit comprises all reagent components required for completing immunoassay, the end part of a solid phase carrier loaded in the kit is coated with a capture antibody, and the solid phase carrier is immersed into each hole in the kit, so that the combination of target antigens in a detected sample and subsequent detection steps can be completed, and the manufacturing and maintenance costs are greatly reduced.
Example 2
First, use method of kit
Injecting a serum sample into a sample hole, putting a solid phase carrier coated with a capture antibody into the sample hole, taking out after 10-60s, sequentially oscillating and cleaning in a first washing hole, a second washing hole and a third washing hole, putting into a detection antibody hole after cleaning, taking out after 10-60s, sequentially oscillating and cleaning in a fourth washing hole and a fifth washing hole, putting into a streptavidin labeled with fluorescein after cleaning for 10-60s, taking out, sequentially oscillating and cleaning in a sixth washing hole, a seventh washing hole and an eighth washing hole, airing, putting into a reading hole, and detecting by adopting a fluorescence analysis detector.
The target antigen in the sample is firstly combined with the capture antibody on the surface of the solid phase carrier, the solid phase carrier is then sequentially immersed into the detection antibody containing the biotin label and the streptavidin labeled with the fluorescein for combination reaction, the surface of the solid phase carrier is coated with the polysaccharide complex with biocompatibility, the nonspecific combination can be effectively resisted, and the amplification of the signal is realized by forming the Cy5-SA molecular layers which are overlapped layer by layer on the surface of the inert polysaccharide matrix. This cyclic labeling reaction can be repeated to further amplify the signal.
Secondly, analyzing the detection result
1. Linearity: the kit establishes a calibration curve by taking the concentration value of the standard substance as an X axis and the luminous value of the standard substance as a Y axis, and calculates the corresponding concentration value according to the luminous value intensity of the sample to be detected, as shown in fig. 2, the linear equation is that Y is 0.7545X-3.7028, R2 is 0.9979, and the minimum detection limit is 0.5 ng/mL.
Taking a D-dimer standard substance with the concentration of 20ng/ml for 10 times of experiments, and calculating a detection concentration value by using a linear equation y which is 0.7545 x-3.7028; as shown in Table 1, the measured average values were 20.113ng/ml, the standard deviation was 0.209, and the intra-batch coefficient of variation was 1.03%.
TABLE 1
2. Stability: the kit is placed for 18 months (the effective period is 12 months) at 4 ℃, the relative deviation between the detection value and the standard value is less than 5 percent, and the kit is relatively stable when stored for 18 months at 4 ℃.
The kit has high accuracy of detection results, good linear relation and good stability, and can be used as an important tool for assisting in judging thrombotic diseases.
Example 3
A preparation method of a kit for detecting D-dimer in blood comprises the following steps:
(1) solid phase support coated capture antibody: soaking the lower end of a quartz needle in a polysaccharide complex for 1-3 minutes, freeze-drying at 4 ℃, diluting a D-dimer capture antibody to 1mg/mL by using 0.01M PBS buffer solution, placing the dried lower end of the quartz needle in the D-dimer capture antibody solution, reacting for 2 hours at 24 ℃ for labeling, washing for 3 times by using 0.1M PBS buffer solution after labeling is finished, and then placing in a confining liquid for confining for 8-12 hours, wherein the confining liquid is Tris-HCl buffer solution containing 1% BSA, 0.1% casein and 3% sucrose, so as to prepare a solid phase carrier for coating the capture antibody;
(2) biotin-labeled detection antibody: d-dimer detection antibody was diluted to 1mg/mL with 0.01M PBS buffer, and the mass ratio of antibody: adding biotin according to the ratio of 1:3-1:5, reacting at 24 ℃ for 8-12 hours for labeling, dialyzing with 0.1M PBS buffer solution for 16-24 hours after labeling, and changing the solution for 3 times to prepare a biotin-labeled detection antibody;
(3) washing buffer solution: 3.58g of Na are weighed2HPO4·12H2O，0.4g KCl，0.54gKH2PO4Adding 800mL of double distilled water for dissolution, adjusting the pH value to 7.4, dissolving to 1000mL to prepare a PBS buffer solution, and calculating and weighing the amount of each raw material required for preparing 1L of the washing buffer solution according to the following concentration: NaCl 0.35M, triton X-100 0.1% vol, sarcosyl 4g/LAnd sodium is weighed and then is placed into the prepared PBS buffer solution to be dissolved and uniformly mixed, so that the washing buffer solution is obtained.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (7)
1. A high-sensitivity D-dimer detection kit is characterized by comprising a kit main body, a sealing cover, a protective cover and a reagent, wherein a solid phase carrier hole, a sample hole, a detection antibody hole, a fluorescein hole, a washing hole and a reading hole are sequentially arranged on the kit main body, a T-shaped structure is arranged inside the solid phase carrier hole, the protective cover is arranged above the solid phase carrier hole and connected with the solid phase carrier hole in a hinged mode, a solid phase carrier is arranged in the solid phase carrier hole, a serum sample is filled in the sample hole, a biotin-labeled detection antibody is filled in the detection antibody hole, a fluorescein-labeled streptavidin is filled in the fluorescein hole, the number of the washing holes is 8, a washing buffer solution is filled in the washing holes, the bottom of the reading hole is transparent, and the sealing cover completely covers the sample hole, the detection antibody hole, the fluorescein hole, the washing hole, The orifice of the reading well.
2. The highly sensitive D-dimer detection kit according to claim 1, wherein said solid support is a quartz needle.
3. The highly sensitive D-dimer detection kit according to claim 1, wherein said protective cover is a protective aluminum foil.
4. The highly sensitive D-dimer detection kit according to claim 1, wherein the lower end of the solid phase carrier is coated with a polysaccharide complex, and the polysaccharide complex is a deionized water solution containing 0.5-2.5% by mass of chitosan, 0.1-0.5% by mass of glycerol, and 0.5-1.5% by mass of polyethylene glycol 1000.
5. The kit for detecting D-dimer according to claim 1, wherein the washing buffer is PBS (0.01M, pH7.4) containing 0.15-0.35M NaCl, 0.05-0.1% vol Triton X-100, and 3-6 g/L sarcosyl.
6. The highly sensitive D-dimer detection kit of claim 1, wherein the diameter of each of the sample well, the detection antibody well and the fluorescein well is D1, the diameter of the washing well is D2, the diameter of the reading well is D3, the diameter of the solid phase carrier well is D4, and the maximum diameter of the solid phase carrier is D5, D5 > D3 > D1 ═ D4 > D2.
7. The use method of the high-sensitivity D-dimer detection kit is characterized by comprising the following steps: injecting a serum sample into a sample hole, putting a solid phase carrier coated with a capture antibody into the sample hole, taking out after 10-60s, sequentially oscillating and cleaning in a first washing hole, a second washing hole and a third washing hole, putting into a detection antibody hole after cleaning, taking out after 10-60s, sequentially oscillating and cleaning in a fourth washing hole and a fifth washing hole, putting into a streptavidin labeled with fluorescein after cleaning for 10-60s, taking out, sequentially oscillating and cleaning in a sixth washing hole, a seventh washing hole and an eighth washing hole, airing, putting into a reading hole, and detecting by adopting a fluorescence analysis detector.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911260674.4A CN110895283A (en) | 2019-12-10 | 2019-12-10 | High-sensitivity D-dimer detection kit and use method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911260674.4A CN110895283A (en) | 2019-12-10 | 2019-12-10 | High-sensitivity D-dimer detection kit and use method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110895283A true CN110895283A (en) | 2020-03-20 |
Family
ID=69787247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911260674.4A Withdrawn CN110895283A (en) | 2019-12-10 | 2019-12-10 | High-sensitivity D-dimer detection kit and use method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110895283A (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020132370A1 (en) * | 2000-02-23 | 2002-09-19 | Lassen Michael Rud | Detection of a blood coagulation activity marker in a body fluid sample |
| US7179660B1 (en) * | 2000-03-06 | 2007-02-20 | Dade Behring Marburg Gmbh | Carriers coated with polysaccharides, their preparation and use |
| US20080221806A1 (en) * | 2005-05-19 | 2008-09-11 | Nanomix, Inc. | Sensor having a thin-film inhibition layer, nitric oxide converter and monitor |
| WO2009049550A1 (en) * | 2007-10-10 | 2009-04-23 | Dalian University Of Technology | Blood vessel scaffold coating of amidoglucosan polysaccharide loaded with cd133 antibody and its preparation method |
| CN101455861A (en) * | 2008-12-17 | 2009-06-17 | 东南大学 | Lubricity coatings preparation method on the medical catheter polymers surface |
| US20100105139A1 (en) * | 2008-10-27 | 2010-04-29 | Remco Alexander Spanjaard | Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents |
| CN101910202A (en) * | 2007-11-07 | 2010-12-08 | 白血球保健股份有限公司 | Biocompatible three dimensional matrix for the immobilization of biological substances |
| CN101978072A (en) * | 2008-01-14 | 2011-02-16 | 超快纳米诊断公司 | Rapid test including genetic sequence probe |
| US20140248642A1 (en) * | 2011-07-19 | 2014-09-04 | Bio Nano Consulting | Apparatus and method for lateral flow affinity assays |
| CN104246500A (en) * | 2012-04-16 | 2014-12-24 | 万迈医疗仪器有限公司 | Wide range luminescent immunoassays |
| CN108949532A (en) * | 2018-10-12 | 2018-12-07 | 宁波奥丞生物科技有限公司 | For detecting the kit of COX-2 gene pleiomorphism |
-
2019
- 2019-12-10 CN CN201911260674.4A patent/CN110895283A/en not_active Withdrawn
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020132370A1 (en) * | 2000-02-23 | 2002-09-19 | Lassen Michael Rud | Detection of a blood coagulation activity marker in a body fluid sample |
| US7179660B1 (en) * | 2000-03-06 | 2007-02-20 | Dade Behring Marburg Gmbh | Carriers coated with polysaccharides, their preparation and use |
| US20080221806A1 (en) * | 2005-05-19 | 2008-09-11 | Nanomix, Inc. | Sensor having a thin-film inhibition layer, nitric oxide converter and monitor |
| WO2009049550A1 (en) * | 2007-10-10 | 2009-04-23 | Dalian University Of Technology | Blood vessel scaffold coating of amidoglucosan polysaccharide loaded with cd133 antibody and its preparation method |
| CN101910202A (en) * | 2007-11-07 | 2010-12-08 | 白血球保健股份有限公司 | Biocompatible three dimensional matrix for the immobilization of biological substances |
| CN101978072A (en) * | 2008-01-14 | 2011-02-16 | 超快纳米诊断公司 | Rapid test including genetic sequence probe |
| US20100105139A1 (en) * | 2008-10-27 | 2010-04-29 | Remco Alexander Spanjaard | Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents |
| CN101455861A (en) * | 2008-12-17 | 2009-06-17 | 东南大学 | Lubricity coatings preparation method on the medical catheter polymers surface |
| US20140248642A1 (en) * | 2011-07-19 | 2014-09-04 | Bio Nano Consulting | Apparatus and method for lateral flow affinity assays |
| CN104246500A (en) * | 2012-04-16 | 2014-12-24 | 万迈医疗仪器有限公司 | Wide range luminescent immunoassays |
| CN108949532A (en) * | 2018-10-12 | 2018-12-07 | 宁波奥丞生物科技有限公司 | For detecting the kit of COX-2 gene pleiomorphism |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3258270B1 (en) | Cardiac troponin i ultra-sensitive detection reagent kit, and ultra-sensitive detection method therefor | |
| CN104730251B (en) | Troponin I detection kit and detection method | |
| CN108254563B (en) | Detect time-resolved fluoroimmunoassay chromatograph test strip, the kit and preparation method thereof of cTnI | |
| CN103278651B (en) | Kit for chemiluminescence immunity quantitative detection of MYO (myohaemoglobinnano) nano magnetic particle and preparation method of kit | |
| CN104730245A (en) | D-dimer detection kit and D-dimer detection method | |
| CN102507947A (en) | CEA TRFIA (time-resolved fluoroimmunoassay) kit based on IMB (immunomagnetic beads) | |
| CN105403693A (en) | Preparation method of magnetic particle chemiluminescence reagent | |
| CN106018347A (en) | Surface plasma resonance sensing chip and preparation method and application thereof | |
| CN102998465A (en) | Quantitative detection kit combining magnetic particles with chemiluminescence immunoassay for angiotensin (Ang) I, and preparation method of kit | |
| CN108445214A (en) | A kind of kit and preparation method quantitatively detecting d-dimer | |
| Chan et al. | Rapid analysis of fatty acid-binding proteins with immunosensors and immunotests for early monitoring of tissue injury | |
| CN101539576A (en) | Hepatitis B virus pre S1 antigen chemiluminscence immunoassay kit and preparation method thereof | |
| CN103675299A (en) | Kit and method for detecting concentration of fibronectin in urine | |
| CN102998462B (en) | Quantitative detection kit combining magnetic particles with chemiluminescence immunoassay for procollagen III (PC III), and preparation method of kit | |
| CN110907654A (en) | Free estriol quantitative detection kit and preparation method thereof | |
| CN111239410A (en) | Kit for detecting liver cancer, hepatitis and/or liver cirrhosis and application of kit in AKR1B10 and AFP combined quantitative determination | |
| CN114487442A (en) | Mouse monoclonal antibody coated magnetic bead, preparation method and kit for determining high-sensitivity cardiac troponin I | |
| Afsarimanesh et al. | Biosensors for the measurement of C-terminal telopeptide of type I collagen (CTX-I) | |
| CN113311171A (en) | Method for detecting glycated serum albumin by using boric acid affinity principle | |
| CN212068784U (en) | Micro-fluidic paper chip for detecting human hypersensitive C reactive protein | |
| CN102095868A (en) | Alpha fetoprotein chemiluminescence quantitive detection kit | |
| CN110895283A (en) | High-sensitivity D-dimer detection kit and use method thereof | |
| CN113376378A (en) | D-dimer detection kit, preparation method and application | |
| CN110441531A (en) | The kit and preparation method of Procalcitonin in a kind of detection blood | |
| CN111487407A (en) | Detection kit for S100B protein and use method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200320 |